Osilodrostat

From Infogalactic: the planetary knowledge core
(Redirected from LCI699)
Jump to: navigation, search

Lua error in Module:Infobox at line 166: malformed pattern (missing ']').

Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, non-steroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome).[1][2] It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1).[2] The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications.[1] As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively.[1]

See also

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


<templatestyles src="Asbox/styles.css"></templatestyles>

  1. 1.0 1.1 1.2 http://adisinsight.springer.com/drugs/800026342
  2. 2.0 2.1 Lua error in package.lua at line 80: module 'strict' not found.